In early systemic therapy, retinoids and interferon-gamma are the first-line options, while targeted molecular drugs and oral histone deacetylase inhibitors such as vorinostat, which is orally administrated as 400 mg, are considered second-line with the efficacy against lymphomas [6,7]. In refractory cases, single-agent or multi-agent chemotherapy and allogeneic hematopoietic stem cell transplantation may be considered. The gene discussed is IFNG; the disease is lymphoma.